TTRX · Insider Trading
Turn Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by TTRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Martin William Dewhurst | Director | A | +71,666 deriv. | — |
| 2026-06-08 | Andrew Gengos | Director | A | +95,000 deriv. | — |
| 2026-06-08 | Arthur F Golden | Director | A | +89,584 deriv. | — |
| 2026-06-08 | Kent Edward Kester | Director | A | +83,334 deriv. | — |
| 2026-06-01 | BEB Holdings, LLC | 10%+ Owner | G | — | — |
| 2026-04-03 | Arthur F Golden | Director | G | +300,000 | — |
| 2026-04-03 | Zuraiz Chaudhary | See Remarks | A | +80,000 deriv. | — |
| 2026-04-03 | Bradley Evan Burnam | Chief Executive Officer | G | −600,000 | — |
| 2026-04-03 | Bradley Evan Burnam | Chief Executive Officer | A | +320,000 deriv. | — |
| 2026-02-04 | Martin William Dewhurst | Director | A | +21,882 | — |
| 2025-12-12 | Zuraiz Chaudhary | See Remarks | Buy | +2,500 | +$8.75K |
| 2025-11-25 | Arthur F Golden | Director | Buy | +9,868 | +$33.95K |
| 2025-11-24 | Arthur F Golden | Director | Buy | +20,532 | +$58.93K |
| 2025-11-21 | Zuraiz Chaudhary | See Remarks | Buy | +2,450 | +$7.07K |
| 2025-11-17 | Zuraiz Chaudhary | See Remarks | Buy | +2,500 | +$9.05K |
| 2025-10-29 | Abraham Chesed | — | Buy | +14,286 | +$65.72K |
| 2025-10-23 | Arthur F Golden | Director | Buy | +20,202 | +$100.00K |
| 2025-10-23 | Zuraiz Chaudhary | See Remarks | Buy | +5,050 | +$25.00K |
| 2025-10-10 | Kent Edward Kester | Director | A | +10,000 | — |
| 2025-10-10 | Andrew Gengos | Director | A | +10,000 | — |
| 2025-10-10 | Zuraiz Chaudhary | See Remarks | A | +240,000 deriv. | — |
| 2025-10-10 | Arthur F Golden | Director | A | +10,000 | — |
| 2025-10-10 | Neilesh Shailesh Ghodadra | Chief Medical Officer | A | +10,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bradley Evan Burnam | Chief Executive Officer | 15,716,260 | $174.61M |
| BEB Holdings, LLC | 10%+ Owner | 15,116,260 | $167.94M |
| Abraham Chesed | — | 1,447,268 | $16.08M |
| Arthur F Golden | Director | 360,602 | $4.01M |
| Martin William Dewhurst | Director | 21,882 | $243.11K |
| Zuraiz Chaudhary | See Remarks | 12,500 | $138.88K |
| Andrew Gengos | Director | 10,000 | $111.10K |
| Kent Edward Kester | Director | 10,000 | $111.10K |
| Neilesh Shailesh Ghodadra | Chief Medical Officer | 10,000 | $111.10K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TTRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.